Organon & Co. (OGN)
NYSE • Healthcare
Last close at October 8, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Organon & Co. keeps $7 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 9
in 31 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Organon & Co. missed consensus on adjusted EPS in the second fiscal quarter of 2026, posting $0.85 versus the $0.90 estimate, roughly -5.7%, and the results were reported on July 31, 2026. Adjusted EPS was down 15% from $1.00 a year ago, operating cash flow was negative about $224.7 million, and the company paid $5.0 million in dividends.
About Organon & Co.
Organon & Co. develops and markets prescription medicines in healthcare, with a portfolio centered on women's health, biosimilars, and established therapies; it trades on the NYSE under OGN and recorded $6.2 billion in revenue in FY2025. The company operates as a drug manufacturer with products used across reproductive care, chronic disease, and allergy treatment.
Today's Snapshot
The day ended with OGN slightly lower at 13.75, in line with a flat sector. At the close, OGN was within 0.4% of its 52-week high of 13.80.
Trading Volume
Above 10d avg 2.0M
2M
vs S&P 500 Today
Moderate Outperformance
+0.25%
Updated: October 8, 2026 at 20:26 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$11.20 - $13.73Buy
- RSI (14)56.85Neutral
- Stochastic %K (14, 3, 3)80.51Sell
- MACD Level (12, 26)0.02Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.